Home › Research › Lewy body dementia
An AIM2 inflammasome biomimetic mineralization inhibitor for vascular dementia therapy
Yueqi Zhang, Yueqi Zhang, Lixian Jiang, Rongrong Wu, Wei Gao, Xiaojie Zhang, Lan Liu, Yaxuan Zhang et al.. Theranostics, 2025-05-25
Topic: Brain proteins, microglia and lab models
: Integrating clinical bioinformatics with computational drug design, this study establishes a translational paradigm for nanomaterial development. M2exo@HMPB serves not only as an AIM2 inflammasome-targeting biomimetic mineralization inhibitor for VaD therapy but also provides new insights for treating AIM2-mediated cell death pathologies.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Zhang, Y., Jiang, L., Wu, R., Gao, W., Zhang, X., Liu, L., et al. (2025). An AIM2 inflammasome biomimetic mineralization inhibitor for vascular dementia therapy. Theranostics. https://doi.org/10.7150/thno.110389
Vancouver
Zhang Y, Jiang L, Wu R, Gao W, Zhang X, Liu L, et al. An AIM2 inflammasome biomimetic mineralization inhibitor for vascular dementia therapy. Theranostics. 2025. doi:10.7150/thno.110389. PMID: 40521199.
BibTeX
@article{zhang2025-40521199,
author = {Zhang, Yueqi and Jiang, Lixian and Wu, Rongrong and Gao, Wei and Zhang, Xiaojie and Liu, Lan and Zhang, Yaxuan and others},
title = {{An AIM2 inflammasome biomimetic mineralization inhibitor for vascular dementia therapy}},
journal = {Theranostics},
year = {2025},
doi = {10.7150/thno.110389},
pmid = {40521199},
url = {https://doi.org/10.7150/thno.110389}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- : Integrating clinical bioinformatics with computational drug design, this study establishes a translational paradigm for nanomaterial development.
- M2exo@HMPB serves not only as an AIM2 inflammasome-targeting biomimetic mineralization inhibitor for VaD therapy but also provides new insights for treating AIM2-mediated cell death pathologies.
Why it matters
This study describes a nanomaterial, M2exo@HMPB, designed to target the AIM2 inflammasome as a possible therapy for vascular dementia, combining clinical bioinformatics with computational drug design. It is early development work and does not report testing in patients, so no treatment, cure or prevention is established.
Study details
- Evidence strengthLow
How this study scored 37/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Theranostics) |
| Journal's citation record | 2 / 4 | Theranostics: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 4 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Jianliang Fu: h-index 23 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Shanghai Jiao Tong University: institution h-index 975 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40521199) |
| Free to read | 2 / 2 | Free to read |
| Total | 37 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Lewy body dementia
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.